bezafibrate has been researched along with niacin in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 8 (34.78) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Cramb, R; Florkowski, CM | 1 |
| Krishnamurthy, A; Thapar, GS | 1 |
| Hambrecht, R; Kübler, W; Schuler, G; Tischbirek, K; von Hodenberg, E | 1 |
| Kostner, GM | 1 |
| Franceschini, G; Paoletti, R; Sirtori, CR | 1 |
| Luria, MH; Sapoznikov, D | 1 |
| Jokubaitis, LA | 2 |
| Sinzinger, H | 1 |
| Friedman, M; Haimov, T; Hoffman, A; Lomnicky, Y; Luria, MH | 1 |
| Isles, CG; Paterson, JR | 1 |
| Kawamori, R; Onuma, T | 1 |
| Matsuzawa, Y; Nagai, Y; Takemura, K; Yamashita, S; Yanagi, K | 1 |
| Mal', GS | 1 |
| Ascaso, JF; Felipe Pallardo, L; Fernández-Cruz, A; González Santos, P; Hernández Mijares, A; Mangas Rojas, A; Millán, J; Pedro-Botet, J; Pérez-Jiménez, F; Pía, G; Pintó, X; Plaza, I; Rubiés-Prat, J | 1 |
| Patel, J | 1 |
| Nagao, M; Oikawa, S | 1 |
| Critchley, WR; Shah, MK; Shaw, SM; Williams, SG; Yonan, N | 1 |
11 review(s) available for bezafibrate and niacin
| Article | Year |
|---|---|
Approaches to the management of hypercholesterolaemia.
Topics: Bezafibrate; Bile Acids and Salts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Probucol | 1992 |
The affection of lipoprotein-a by lipid lowering drugs.
Topics: Arteriosclerosis; Bezafibrate; Cholestyramine Resin; Hormones; Humans; Hypolipidemic Agents; Lipoprotein(a); Lipoproteins; Neomycin; Niacin; Nicotinic Acids; Stanozolol | 1988 |
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Randomized Controlled Trials as Topic | 1996 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dietary Supplements; Female; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Male; Middle Aged; Niacin; Patient Selection; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Triglycerides | 2000 |
[Drug combination therapies for patients with hyperlipidemia and its significance].
Topics: Anion Exchange Resins; Bezafibrate; Cholesterol, LDL; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin | 2001 |
[Treatment of high blood cholesterol in patients with coronary heart disease].
Topics: Anion Exchange Resins; Bezafibrate; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Niacin; Probucol; Risk Factors | 1994 |
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Assessment | 2004 |
Dyslipidaemia in diabetes.
Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin | 2006 |
[Intervention for hypertriglyceridemia].
Topics: Aged; Bezafibrate; Clofibric Acid; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Humans; Hypertriglyceridemia; Male; Middle Aged; Niacin | 2007 |
Second line options for hyperlipidemia management after cardiac transplantation.
Topics: Azetidines; Bezafibrate; Diet; Exercise; Ezetimibe; Fish Oils; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin | 2013 |
4 trial(s) available for bezafibrate and niacin
| Article | Year |
|---|---|
Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.
Topics: Adipose Tissue; Animals; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Bezafibrate; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipolysis; Lipoproteins, HDL; Niacin; Rats; Structure-Activity Relationship | 1983 |
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Randomized Controlled Trials as Topic | 1996 |
[Comparative efficiency of prolonged diet and drug therapies for hyperlipidemias in patients with ischemic heart disease].
Topics: Aged; Bezafibrate; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Ischemia; Niacin; Time Factors | 2004 |
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Randomized Controlled Trials as Topic | 1994 |
9 other study(ies) available for bezafibrate and niacin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Effect of bezafibrate & nicotinic acid on triton induced hyperlipidemias in CFY rats.
Topics: Animals; Bezafibrate; Cholesterol; Drug Therapy, Combination; Hyperlipidemias; Male; Niacin; Polyethylene Glycols; Rats; Triglycerides | 1991 |
[Type III hyperlipoproteinemia in monoclonal IgM gammopathy].
Topics: Adult; Bezafibrate; Cholesterol; Dietary Fats; Female; Humans; Hypergammaglobulinemia; Hyperlipoproteinemia Type III; Immunoglobulin lambda-Chains; Immunoglobulin M; Lipids; Lovastatin; Niacin; Triglycerides | 1991 |
Raising HDL cholesterol with low-dose nicotinic acid and bezafibrate: preliminary experience.
Topics: Aged; Bezafibrate; Cholesterol, HDL; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Niacin; Triglycerides | 1993 |
Pharmacodynamic effects of bezafibrate and niacin combination: implications of the mode of administration.
Topics: Animals; Bezafibrate; Cholesterol; Drug Therapy, Combination; Hyperlipidemias; Hypolipidemic Agents; Male; Niacin; Rats; Rats, Inbred Lew; Triglycerides | 2000 |
Beyond statins: assessing the alternatives. Some people can't tolerate statins, and others need additional medications to achieve healthy cholesterol levels.
Topics: Anticholesteremic Agents; Azetidines; Bezafibrate; Cholesterol; Dietary Supplements; Exercise; Ezetimibe; Health Behavior; Health Promotion; Humans; Hyperlipidemias; Niacin | 2014 |